These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16625865)

  • 21. Candidates for peptide receptor radiotherapy today and in the future.
    Reubi JC; Mäcke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():67S-75S. PubMed ID: 15653654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatostatin analogs for the treatment of neuroendocrine tumors.
    Culler MD; Oberg K; Arnold R; Krenning EP; Sevilla I; Díaz JA
    Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():9-17. PubMed ID: 21369878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors.
    Giovacchini G; Nicolas G; Forrer F
    Anticancer Agents Med Chem; 2012 Jun; 12(5):526-42. PubMed ID: 22292758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.
    Taïeb D; Garrigue P; Bardiès M; Abdullah AE; Pacak K
    PET Clin; 2015 Oct; 10(4):477-86. PubMed ID: 26384594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy.
    Teunissen JJ; Kwekkeboom DJ; de Jong M; Esser JP; Valkema R; Krenning EP
    Best Pract Res Clin Gastroenterol; 2005 Aug; 19(4):595-616. PubMed ID: 16183530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
    Janson ET
    J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.
    Pauwels S; Barone R; Walrand S; Borson-Chazot F; Valkema R; Kvols LK; Krenning EP; Jamar F
    J Nucl Med; 2005 Jan; 46 Suppl 1():92S-8S. PubMed ID: 15653657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
    Miederer M; Henriksen G; Alke A; Mossbrugger I; Quintanilla-Martinez L; Senekowitsch-Schmidtke R; Essler M
    Clin Cancer Res; 2008 Jun; 14(11):3555-61. PubMed ID: 18519789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy.
    Smith MC; Liu J; Chen T; Schran H; Yeh CM; Jamar F; Valkema R; Bakker W; Kvols L; Krenning E; Pauwels S
    Digestion; 2000; 62 Suppl 1():69-72. PubMed ID: 10940690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lutetium-177 Labeled Peptides: The European Institute of Oncology Experience.
    Carollo A; Papi S; Chinol M
    Curr Radiopharm; 2016; 9(1):19-32. PubMed ID: 25771368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiolabelled somatostatins: towards the magic bullet?
    Buscombe JR; Caplin ME; Mielcarek W
    Nucl Med Commun; 1999 Apr; 20(4):299-301. PubMed ID: 10319345
    [No Abstract]   [Full Text] [Related]  

  • 32. Therapy: Neuroendocrine cancer--are two radionuclides better than one?
    Kwekkeboom DJ
    Nat Rev Endocrinol; 2012 May; 8(6):326-8. PubMed ID: 22547261
    [No Abstract]   [Full Text] [Related]  

  • 33. [Peptide receptor radionuclide therapy of neuroendocrine tumors].
    Arveschoug AK; Hjorthaug K; Rehling M; Højgaard L; Mortensen J; Oturai PS
    Ugeskr Laeger; 2009 Mar; 171(13):1073. PubMed ID: 19321068
    [No Abstract]   [Full Text] [Related]  

  • 34. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
    de Visser M; Verwijnen SM; de Jong M
    Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations.
    Sarnelli A; Guerriero F; Botta F; Ferrari M; Strigari L; Bodei L; D'Errico V; Grassi E; Fioroni F; Paganelli G; Orecchia R; Cremonesi M
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):216-231. PubMed ID: 26576734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dosimetry for treatment with radiolabelled somatostatin analogues. A review.
    Cremonesi M; Botta F; Di Dia A; Ferrari M; Bodei L; De Cicco C; Rossi A; Bartolomei M; Mei R; Severi S; Salvatori M; Pedroli G; Paganelli G
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):37-51. PubMed ID: 20168285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.
    Basu B; Sirohi B; Corrie P
    Endocr Relat Cancer; 2010 Mar; 17(1):R75-90. PubMed ID: 20008097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Yttrium-labelled peptides for therapy of NET.
    Bodei L; Cremonesi M; Grana CM; Chinol M; Baio SM; Severi S; Paganelli G
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S93-102. PubMed ID: 22388625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs.
    Teunissen JJ; Kwekkeboom DJ; Krenning EP
    Trends Endocrinol Metab; 2006; 17(1):19-25. PubMed ID: 16311041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peptide Receptor Radiotherapy Comes of Age.
    Al-Toubah T; Strosberg J
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):615-625. PubMed ID: 30098719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.